Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
2. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
3.Tiene citas relacionadas
McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S, for the INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33. [Ref.ID 83625]
4.Tiene citas relacionadas Cita con resumen
Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J, on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324:699-702. [Ref.ID 60835]
5.Tiene citas relacionadas
Pressel S, Davis BR, Louis GT, Whelton P, Adrogue H, Egan D, Farber M, Payne G, Probstfield J, Ward H, for the ALLHAT Research Group. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Control Clin Trial 2001;22:1967-75. [Ref.ID 60624]
6. Cita con resumen
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Díaz R, Probstfield J, for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1. [Ref.ID 60087]
7.Tiene citas relacionadas
Wittes J, Lakatos E, Black D, Geraci B, Davis B, Moyé L, Probstfield J. Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. Control Clin Trial 1999;20:121-32. [Ref.ID 45322]
8.
Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8. [Ref.ID 14945]
9.
Bergman A, Probstfield J, Wedgewood R. Performance analysis in paediatric practice. J Med Educ 1967;42:262-7. [Ref.ID 5059]
Seleccionar todas
 
 1 a 9 de 9